MTATP6P4

Across TCGA pan-cancer cohorts, MTATP6P4 RNA is linked to patient survival in 5 of 34 cancer types, making it the most broadly survival-associated MTATP6P4 data layer.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher MTATP6P4 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTATP6P4 expression acts as an unfavorable survival marker, although some lineages such as LAML show a favorable association.

KIRC, STAD, and LAML are the cancer types where MTATP6P4 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Tertile	IV	0.186	0.623	<.001	96	view →
STAD	OS	Tertile	II,III,IV	0.533	0.705	.003	26	view →
LAML	DFS	Tertile	All	1.000	0.515	.004	18	view →
LGG	DFS	Tertile	All	0.423	0.774	<.001	15	view →
COAD	DFS	Tertile	II,III,IV	0.298	0.651	.049	9	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MTATP6P4–KIRC (DFS)

Open the KIRC breakdown →